For Indian pharmaceutical companies, this scenario presents a distinct opportunity. Leveraging their established expertise and leadership in global COVID-19 vaccine distribution, along with robust supply chain efficiencies, Indian firms are strategically positioned to capitalize on this market shift. The departure of Chinese players from the market opens a significant gap, which Indian companies are well-equipped to fill .
Fall in provisions help ICICI Bank’s net profit in Q4 FY26
ICICI Bank’s net profit rose 9% to Rs 13,702 crore in March 2026, driven by stable loan growth and a significant drop in provisions. Total